A Long-term Follow-up Study of Subjects With Malignancies Treated With CRISPR CAR Cellular Therapies

Status

Recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512479-11-00

Acronym

CRSP-ONC-LTF

Enrollment

Registered

2024-05-31

Start date

2024-07-26

Completion date

Unknown

Last updated

2025-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematologic Malignancy, Solid Malignancy

Brief summary

Incidence of adverse events, including serious adverse events related to CRISPR CAR cellular therapy and adverse events of special interest

Detailed description

Overall survival, Duration of remission/response

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Incidence of adverse events, including serious adverse events related to CRISPR CAR cellular therapy and adverse events of special interest	—

Secondary

Measure	Time frame
Overall survival, Duration of remission/response	—

Countries

Germany

Outcome results